Patrys adds to antibody portfolio

Human antibody therapy specialists Patrys announced today that is has acquired a new anti-cancer antibody which has been shown to significantly reduce gastric and pancreatic tumours in animal models of human cancers.

Acquired from multinational pharma Debiopharm Group for an undisclosed amount, PAM-1 was originally developed by German research company OncoMab GmbH. In 2007 Patrys acquired all of the company’s technology and assets, but this was after it had sold the rights to its more mature products, including PAM-1 and SC-1, to Debiopharm.

SC-1 is a natural human antibody that has been shown in clinical trials to improve survival rates for sufferers of gastric cancer, and was acquired by Patrys from Debiopharm last year.

“SC-1 gave us a product with positive data from a human clinical trial so that the acquisition turned Patrys into clinical stage company,” Patrys CEO Dan Devine said.

“With the acquisition of PAM-1, a very promising, IgG antibody, we have further enhaced the diversity and depth of our pipeline.”